Ziyi Li | Computational Biology | Best Researcher Award

Published on by Biotechnology Scientist

Dr. Ziyi Li | Computational Biology | Best Researcher Award

Assistant Professor at University of Texas | MD Anderson Cancer Center | Department of Biostatistics | United States

Dr. Ziyi Li is an accomplished researcher and academic whose career reflects a strong commitment to advancing science and technology through innovative research, teaching, and collaboration. He earned his Ph.D. in [insert specialization] from [insert university and year], following earlier academic achievements that laid a solid foundation in [related field]. Over the years, Dr. Li has held significant professional positions, including roles as a lecturer, assistant professor, and research fellow at esteemed institutions, where he has combined teaching excellence with cutting-edge research. His professional journey includes contributions to high-impact projects supported by national and international funding bodies, participation in cross-disciplinary collaborations, and mentorship of graduate and postgraduate students, all of which highlight his leadership in academic and applied research. Dr. Li’s research interests span [insert areas, e.g., artificial intelligence, biomedical engineering, materials science], with a particular focus on developing innovative solutions to real-world problems, such as [insert applied area]. He has consistently demonstrated expertise in advanced methodologies, including experimental design, data analytics, computational modeling, machine learning algorithms, and laboratory-based techniques, which have enabled him to publish in leading peer-reviewed journals indexed in Scopus, IEEE, and Web of Science, as well as present at international conferences. His research skills extend to project management, proposal writing, interdisciplinary collaboration, and the ability to integrate theory with practical applications, making him a versatile scholar in his domain. Recognized for his academic and professional excellence, Dr. Li has received prestigious awards and honors, such as [insert awards, fellowships, or scholarships], and has been actively involved in professional memberships with organizations like [IEEE, ACM, or relevant associations], further enriching his contributions to the global scientific community. Through his work, he continues to influence both academia and industry, advancing knowledge while fostering innovation and sustainability. In conclusion, Dr. Ziyi Li exemplifies the qualities of a dedicated researcher, educator, and innovator whose achievements not only showcase academic brilliance but also reflect his vision for addressing global challenges through impactful science, making him a valuable contributor to his field and an inspiration to future generations of researchers.

Profile: Orcid | Google Scholar

Featured Publications

Li, L., Zang, L., Zhang, F., Chen, J., Shen, H., Shu, L., Liang, F., Feng, C., Chen, D., & Li, Z. (2017). Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. Human Molecular Genetics, 26(13), 2398–2411.

Lal, B. K., Zhou, W., Li, Z., Kyriakides, T., Matsumura, J., Lederle, F. A., Freischlag, J., & Veterans Affairs Open Versus Endovascular Repair (OVER) Trial Investigators. (2015). Predictors and outcomes of endoleaks in the Veterans Affairs Open Versus Endovascular Repair (OVER) trial of abdominal aortic aneurysms. Journal of Vascular Surgery, 62(6), 1394–1404.

Kang, Y., Zhou, Y., Li, Y., Han, Y., Xu, J., Niu, W., Li, Z., Liu, S., Feng, H., Huang, W., … (2021). A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies. Nature Neuroscience, 24(10), 1377–1391.

Li, Z., & Wu, H. (2019). TOAST: Improving reference-free cell composition estimation by cross-cell type differential analysis. Genome Biology, 20(1), 190.

Ganan-Gomez, I., Yang, H., Ma, F., Montalban-Bravo, G., Thongon, N., … Li, Z. (2022). Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 28(3), 557–567.

Li, Z., Jiang, X., Wang, Y., & Kim, Y. (2021). Applied machine learning in Alzheimer’s disease research: Omics, imaging, and clinical data. Emerging Topics in Life Sciences, 5(6), 765–777.

Cheng, Y., Sun, M., Chen, L., Li, Y., Lin, L., Yao, B., Li, Z., Wang, Z., Chen, J., & Miao, Z. (2018). Ten-Eleven Translocation proteins modulate the response to environmental stress in mice. Cell Reports, 25(11), 3194–3203.e4.

Liquan Wu | Neuroscience | Best Researcher Award

Published on by Biotechnology Scientist

Dr. liquan wu | Neuroscience | Best Researcher Award

Senior Neurosurgeron at Renmin Hospital of Wuhan University, China

Dr. Liquan Wu is a distinguished neurosurgeon and neuroscientist, currently serving as a senior surgeon at the Department of Neurosurgery, Renmin Hospital of Wuhan University. With over two decades of dedication to neuroscience and clinical neurosurgery, Dr. Wu has emerged as a leading figure in cerebral ischemia, glioma research, and translational neuromedicine. His academic and research contributions have significantly advanced the understanding of neuroprotection, neuroinflammation, and glioma stem cell biology. Blending clinical excellence with scientific innovation, he continues to bridge bench-side discoveries with bedside applications.

Profile

Scopus

Education:

Dr. Wu’s academic journey reflects a consistent focus on neurosurgical and neuroscience disciplines. He obtained his M.D. from Wuhan University in 2003, followed by a Master’s degree in Neuroscience and Neurosurgery in 2006. To further deepen his expertise, he pursued and completed a Ph.D. in Neuroscience and Neurosurgery from the same institution in 2013. This rigorous academic foundation laid the groundwork for his dynamic career in both clinical and experimental neuroscience.

Experience:

Dr. Wu began his clinical career as a resident in the Department of Neurosurgery at Renmin Hospital, Wuhan University, between 2006 and 2009. He then served as an attending physician and advanced to associate senior surgeon from 2013 to 2021. He currently holds the position of senior surgeon since 2021. Notably, he completed a prestigious research fellowship at Harvard Medical School’s Brigham and Women’s Hospital from 2015 to 2016, enhancing his international exposure to neurosurgical research. His clinical acumen is matched by his technical expertise in brain ischemia models, glioma surgeries, and molecular neurobiology.

Research Interest:

Dr. Wu’s research interests are centered on cerebral ischemia-reperfusion injury, neuroprotection, ferroptosis regulation, and glioma stem cell behavior. He investigates molecular pathways such as PLK1 deubiquitination, Akt activation, and NF-kB modulation, which are crucial in neural injury and repair. He also explores the interface between metabolic profiling and neurosurgical pathology, using advanced proteomics and bioinformatics tools. His innovative studies incorporate machine learning, nanotechnology, and immunomodulation, positioning him at the forefront of translational neuro-oncology.

Award:

Throughout his career, Dr. Wu has been honored with several prestigious research grants and recognitions. He has received the Natural Science Foundation of Hubei Province grant and multiple research project awards from Wuhan University. As both Principal Investigator and Co-Principal Investigator, he has been instrumental in securing and executing projects funded by the National Science Foundation of China, focusing on cancer stem cells, drug resistance in gliomas, and targeted vaccine therapies. These accolades reflect his impact on both scientific discovery and clinical practice.

Publication:

Dr. Wu has contributed extensively to high-impact peer-reviewed journals. A selection of his recent works includes:

  1. Wu LQ et al. (2025). “The deubiquitinase OTUD3 plays a neuroprotective role…” Clin Transl Med, 15(5):e70347.
  2. Ding R, Wu LQ et al. (2024). “Multi-targeted olink proteomics analyses…” Proteome Sci, 22(1):11.
  3. Cheng J, Wu LQ et al. (2024). “Mxene-bpV plays a neuroprotective role…” J Mater Sci Mater Med, 35(1):42.
  4. Ding R, Wu LQ et al. (2024). “Identification of metabolic components…” Rapid Commun Mass Spectrom, 38(14):e9763.
  5. Qin X, Wu LQ et al. (2023). “Identification of anoikis-related genes…” Front Aging Neurosci, 15:1142163.
  6. Cheng J, Wu LQ et al. (2023). “Overexpressing SIRT6 can attenuate the injury…” Neuromolecular Med, 25(1):53-63.
  7. Wu LQ (2022). “Electroacupuncture for Spinal Cord Injury…” Neurospine, 19(3):770-772.
    These publications demonstrate Dr. Wu’s multidisciplinary expertise, ranging from clinical trials and biomarker discovery to neural tissue engineering and systems biology.

Conclusion:

Dr. Liquan Wu exemplifies excellence in both the clinical and scientific arenas of neurosurgery. His robust educational background, international research exposure, and groundbreaking investigations into neuroprotection and glioma therapy mark him as a leading contributor in his field. With impactful publications, funded projects, and clinical service, Dr. Wu is a worthy nominee for the “Best Researcher Award.” His continued dedication to unraveling the molecular intricacies of brain injury and regeneration is not only advancing scientific knowledge but also transforming patient care in neurosurgical practice.